## We Know A Lot About Cannabis

Trecia Ehrlich, MPH

Research Consultant, Washington State Liquor and Cannabis Board Using research to reframe how we think about Cannabis

#### Disclaimer

- Today's presentation is intended to inform the audience around the scope of research on cannabis as it relates to a better understanding cannabis and public health. It aims to provide both information from research, as well as a framework for analyzing that research.
- The views expressed today represent the speaker's summary of that process, and do not necessarily reflect the views of the Washington State Liquor and Cannabis Board.
- The speaker is not (necessarily) intending to defend any research presented, but instead share the research observed.

#### What is research?

Research comprises "creative and systematic work undertaken to increase the stock of knowledge, including knowledge of humans, culture and society, and the use of this stock of knowledge to devise new applications."

-The Organization for Economic Cooperation and Development

Research isn't intended to be right, it's intended to add truth.

#### Hazardous Journeys

#### Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials

*BMJ* 2003 ; 327 doi: https://doi.org/10.1136/bmj.327.7429.1459 (Published 18 December 2003) Cite this as: *BMJ* 2003;327:1459

Article Related content Metrics Responses

Gordon C S Smith (8css2@cam.ac.uk), professor 1, Jill P Pell, consultant 2

Author affiliations 🗙

<sup>1</sup>Correspondence to: G C S Smith

Abstract

Objectives To determine whether parachutes are effective in preventing major trauma related to

DA	<b>ILY NEV</b>	VS			
World - Bus	iness - Finance - Lifestyle - Travel - Sport	- Weather			
ssue: 240104	4 THE WORLDS BEST SELLING NATIONAL NEWSPAPER				

## 59% Of You Will Share This Article Without Even Reading It

### The research on regulation

- Most research on regulation focuses on public opinion and efficacy of alcohol and tobacco regulations.
- The most effective policy interventions for reducing the health burdens and societal costs of alcohol are:
  - Reducing or restricting outlet density
  - Restricting advertising
  - Increasing prices (1)
- Providing constituents with information and education about the adverse health effects of a substance, or the effectiveness of an intervention increases support for the associated regulation. (1,2)


### The Challenges of Cannabis Research

Classification as a Schedule 1 Federal Controlled Substance

- Prevents some human subjects research, challenges funding streams, limits the type of cannabis available for testing
- Polysubstance use makes it difficult to isolate the effects of cannabis from those of tobacco or alcohol
- Much of research funding is provided to states that have not legalized retail use
  - Challenges understanding the effects of legalization and understanding different sociopolitical and economic contexts

#### Where is cannabis research happening?

- Washington \$4.66 million
- California \$26.19 million
- New York \$12.47 million
- Michigan \$11.39 million
- Connecticut \$8.49 million
- Colorado \$6.97 million
- Oregon- \$3.94 million



### NIH Reporter Tool

Search Kesuits		Back to Qu	uery Form	Save Query	Share Query				
			Ехр	All Projects	▼ GO				
PROJECTS ? PUBLICATIONS PATENTS CLINICAL STUDIES DATA & VISUALIZE MAP NEWS & MORE 1									
There were 358 results matching your search criteria . Records per page 25 🔻			Sho	w/Hide Search Crit	teria 🥪				
Click on the column header to sort the results     1 2 3 4 13 14 15			Page	1 of 15 Next La	<u>st</u> > >>				
T: Application Type; Act: Activity Code; Project: Admin IC, Serial No.; Year: Support Year/Supplement/Amendment									
T Act Project Year Sub # Project Title Contact Pl/ Project Leader Organization	FY /	Admin IC	Funding IC	FY Total Cost by IC	Similar Projects				
4 R01 DA023668 09 CANNABIS AND TOBACCO INVOLVEMENT: A TWIN STUDY AGRAWAL, ARPANA WASHINGTON UNIVERSITY 2	2016	NIDA	NIDA	\$289,034	Ð				
5 K02 DA032573 07 DELINEATING THE ROLE OF GENETIC INFLUENCES ON CANNABIS INVOLVEMENT AGRAWAL, ARPANA WASHINGTON UNIVERSITY 2	2018	NIDA	NIDA	\$119,134	e				
5   R01   DA040411   03   CANNABIS, DEPRESSION AND SUICIDAL THOUGHTS AND BEHAVIORS   AGRAWAL, ARPANA et UNIVERSITY   WASHINGTON UNIVERSITY   2	2017	NIDA	NIDA	\$381,250	e				
2 R01 DA027232 05A1   EFFECT OF SEX DIFFERENCES AND CONCURRENT CANNABIS USE ON STRESS-RELATED PSYCHOBIOLOGICAL MECHANISMS ASSOCIATED WITH SMOKING CESSATION AND RELAPSE   AL'ABSI, MUSTAFA N. MINNESOTA   UNIVERSITY OF MINNESOTA   2	2017	NIDA	NIDA	\$397,279					
5 K99 AT009156 02   USING PRE-CLINICAL BIOMARKERS     AND EPIDEMIOLOGICAL MODELS TO   ALSHAARAWY,   MICHIGAN STATE     ASSESS THE EFFECTS OF   OMAYMA O   UNIVERSITY     CANNABINOIDS ON DISEASE   OMAYMA O   UNIVERSITY	2017	NCCIH	NCCIH	\$90,591	B				
5 R01 DA040716 02   NEUROCOGNITIVE CONSEQUENCES OF ADOLESCENT ANOKHIN, ANDREY P. MARIJUANA USE   WASHINGTON UNIVERSITY   2	2018	NIDA	NIDA	\$599,842					
5   R01   DA039924   03   ECOLOGICAL MOMENTARY ASSESSMENT OF CANNABIS USE EFFECTS IN YOUNG ADULTS   ANSELL, EMILY B UNIVERSITY   SYRACUSE UNIVERSITY   2	2018	NIDA	NIDA	\$423,990	Ð				




#### HOME | ABOUT REPORT | FAQS | GLOSSARY | CONTACT US

QUICK LINKS RESE	EARCH	ORGANIZA	TIONS	WORKFO	DRCE	FUNDING	RE	PORTS	LINKS &	DATA
Home > RePORTER > Search Results					M∕ RePORT	ER Login	Register   Re	PORTER Manu	al System Heal	th: GREEN
Search Results							Back to Q	uery Form		Share Query
PROJECTS ? PUBLICATIONS P There were 3 results matching your se	earch criteria .	ICAL STUDIES DA	TA & VISUALIZE	MAP NEWS	& MORE 匠				//Hide Search Crit	
Click on the column header to sort the results T: Application Type; Act: Activity Code; Project: Admin IC, Serial No.; Year: Support Year/Supplement/Amendment										
T Act Project Year Sub#	Project Title	2	Contac Project	t PI/ : Leader	Organization	FY	Admin IC		FY Total Cost by IC	Similar Projects
5 R01 DA039707 03	INNOVATIVE	HARM REDUCTION STRATEGIES FOR G NEW KNOWLEDG	HUTCH	ISON <u>, KENT E</u>	UNIVERSITY O COLORADO	F 201	8 NIDA	NIDA	\$478,010	
<u>1 R01 DA043475 01A1</u>	CANNABINO	L PHARMACOLOGY ID AND TERPENOID	D VANDRI	<u>EY, RYAN G</u>	JOHNS HOPKIN UNIVERSITY	NS 201	7 NIDA	NIDA	\$716,141	
<u>1 R01 DA045003 01</u>	COMPARATIN	VE PHARMACOLOG	GY OF DDELS WILEY,	JENNY L.	RESEARCH TR	IANGLE 201	8 NIDA	NIDA	\$526,837	

#### What is cannabis composed of?

The aromatic compound of cannabis. A natural pesticide attracting pollinators and repelling predators, attracting beneficial predators. Provides odor to the plant, and works synergistically with cannabinoids to moderate or modulate their effects.



The most common cannabinoid is THC (psychoactive). CBD is known for anti-inflammatory and antiepileptic properties. THCA is the precursor to THC. CBG and CBN are known as appetite stimulants and anti-emetics.




Linalool- relaxant



Humulene - Anti- Myrce inflammatory effec

Myrcene- Sedative, effect modulator




Provides pigmentation (greens and purples), contribute to odor and flavor. Some therapeutic indications (anti-fungal, antioxidant). Protects plant from UV rays. The most understudied, and least understood of cannabis compounds.

# Let's do some math! Thinking about dosage and potency

#### 1 gram joint = 1000 mg



- Myrcene: 0.84% = 8.4 mg
- Limonene: 0.67 % = 6.7 mg
- bCaryophyllene: 0.28% = 2.8 mg
- bPinene: 0.22% = 2.2 mg
- THC: 19.52% = 195 mg
- CBD 0.32% = 3.2 mg
- Examples of dosages studied: Myrcene @ 100mg/kg weight (in mice). CBD @ 20mg/kg weight (in pediatric epilepsy patients).



### Cannabis Advertising, Information Sharing, & Social Media

- 77% of past month marijuana users who viewed marijuana advertisements saw them through social media. (3)
- In a study of Washington State cannabis retailers who advertised on weedmaps;
  - ▶ 35% had no age verification on their sites
  - ▶ 44% made health claims about the benefits of marijuana (4)
- In a survey of 742 current marijuana users, 1/3 of users had viewed a marijuana product review in the last 30 days. (5)



### Social Media continued...

- In a content analysis of 116 YouTube videos about dabbing, 89% showed at least one person dabbing, and 54% made mention of medical marijuana. Twenty-one percent contained a brief cautionary message. (6)
- In an analysis of a popular pro-marijuana twitter handle @stillblazingtho (~1 million followers), 73% of followers were under the age of 19, and were disproportionately African American (42.55%) or Hispanic (11.95%) when compared to twitter averages. (7)
- In an analysis of 5,000 randomly sampled tweets about marijuana dabbing, 45% of tweeters expressed dabbing with an intention to pass out. <sup>(8)</sup>

.II Verizon LTE 12:58 PM @ 1 \* -

## Pharmaceutical or fun?



Follow

all that you do, thank you to the mothers out there. Show your gratitude by hooking up mom with something she really needs!

#instagood #weedporn #nugporn #love #beautiful #kush #frost #420 #bud #thc #growcannabis #stoner #highsociety #marijuana #cannabis #cannabiscommunity #smokeweedeveryday #maryjane #710life #dabstagram #legalweed #weedstagram #dank #garden #hightimes #cbd

QΩ 35 likes MAY 12




+

Q

(1)

0


#### Same, same- but different...





### Potency

- High THC cannabis is more strongly associated with cannabis dependence.
- Market-wide increases in THC potency are associated with population level increases of first-time entry into addiction treatment. (10)
- A growing number of case studies have been reported in regard to cardiotoxicity after dabbing, with patients presenting with tachycardia, hypertension, hyperthermia, and severe agitation. (11)
- CBD may attenuate some of the negative effects of THC, acting as an antagonist to some of the psychoactive effects and cognitive impairments associated with THC CBD may have neuroprotective properties when used in conjunction with THC. (11, 13, 14)



#### **Potency continued**

- Butane Hash Oil (BHO, concentrate) use is associated with greater risk (RR=1.8) of physical dependence, academic/occupational issues, impaired control, and poor self care- even after controlling for sociodemographic factors, age of onset, and frequency of use. (12)
- Issues relating to the adverse effects of potency are not necessarily isolating the negative effects of THC, but may be indicative of problems relating to very low amounts of CBD in popular strains and extracts.

### Cannabinoid Hyperemesis Syndrome

First described in 2004, cannabinoid hyperemesis syndrome (CHS) is characterized by episodic vomiting that is often relieved by hot water bathing or compulsive showering. Symptoms typically present after chronic, heavy cannabis use. Symptoms resolve with abstinence from cannabis use. (15)

- CHS has become more prevalent with increases in cannabis use and potency. (16)
- It is difficult to identify the incidence and prevalence of CHS, as the disease is poorly understood, and often underreported or misdiagnosed. In 2014, prevalence data suggested that somewhere between 2.1 and 3.4 million individuals have suffered from CHS since it's first description in 2004. (17)




## States that legalized medical marijuana had 25% fewer opioid-related deaths.

## weedmaps

October 2014 Medical Cannabis Laws & Opioid Analgesic Overdose Mortality in the United States, 1990-2010, Marcus A. Bachhuber et. Al. (JAMA Intern Med.)



#### **Cannabis and Opioids**



How overdose deaths rippled across the United States. Haeyoun Park and Matthew Bloch/The New York Times

#### **Cannabis and Opioids**

- Really challenging to disentangle correlation and causation.
  - Epidemic started at the same time as the initiation of MCL's.
  - Research around associations between changing cannabis laws and opioid death rates have not controlled for the liberalization of naloxone (Narcan).
  - Many states with legal cannabis laws also have more resources for people experiencing opioid addiction.
- Cannabis has been proven to help with pain management and sleep dysfunction, much like opioids. (18)
- Ethnographic and qualitative research suggests that those living with chronic conditions are using cannabis as an alternative to, complimentary with, or tapering from opioids, with some able to significantly reduce their usage. (19)
- Problematic use, as defined by the DSM IV was more common among those prescribed opioids for chronic pain (52.6%) than those using cannabis medicinally for chronic pain (21.2%). (22)


#### **Cannabis for Medical Patients**

#### Post Traumatic Stress Disorder

- CB1 receptors in the hippocampal region have a prominent role in anxiety, the consolidation of fear related memories, and fear related behavior. Cannabinoids specifically target these receptors, while simultaneously aiding in acute symptom relief (including insomnia and stress). (28)
- Chronic Pain
  - Cannabis for pain management dates back to 2900 BC, where it was recommended in ancient Chinese texts in the treatment of rheumatic pain, and was mixed with wine to anesthetize patients during surgical procedures. (29)
  - Patients have reported reduced pain after administration with THC, however dosage, ideal routes of administration, and side effect profiles are still not clinically understood. (29)
- Cannabis has been tested for medical use for a variety of conditions including but not limited to; Alzheimer's disease, anorexia nervosa, anxiety, dementia, dystonia, Huntington's disease, Parkinson's disease, Tourette syndrome, glaucoma, HIV, cancerrelated nausea, ALS, MS, and more.

# Cannabis for Medical Patients continued...

- Plant composition, specifically as it relates to terpenes and cannabinoids may have greater implications in medical dosing and strain type than commonly understood. (30)
- Cannabis has been found helpful in reducing patient reports of spasticity, pain, and stiffness in patients with MS. (31)
- Doctors report low-self efficacy in advising patients on the use, dosage, phytochemical composition of cannabis for their health conditions. (32)



NB Clinic review occurred on days 14 and 42

Source: Wade, DT. Et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized-placebo controlled study on 160 patients. Mult Scler. 2004 Aug: 10(4) 434-441.

### **Cannabis Testing**

- In a study of medical cannabis edibles in 2015 (75 products from 47 brands), THC content in 17% of products were accurately labeled, 23% were underlabeled, and 60 percent were overlabeled. (33)
- In an analysis of cannabis strains across Washington State, a research team found what they described as "systematic variability" between the cannabinoid content reported by different labs, with variations as wide as 6 percentage points of THC between different labs. (34)
- The chemical compounds (like THC and CBD) are not evenly distributed throughout the plant, therefore variations in potency (to some degree) are to be expected.
- Testing variability is common in many new industries, including nutrition and pharmaceuticals. Some of this variability has reduced over time. (35)

#### Cannabidiol - CBD

- A CBD based pharmaceutical, Epidiolex, was recently approved by the FDA for pediatric epilepsy.
- CBD for pediatric epilepsy is typically dosed at 20/mg/kg/day (approximately 400mg). (36)
- CBD has been shown to have anti-inflammatory and anxiolytic effects, however dosage has not been specified. (30)
- Dosage may have important implications for consumers concerned about cost/efficacy relative to other options.

### Worker Safety

- Exposure to molds and allergens (terpenes) can cause rhinitis and contact dermatitis after prolonged exposures. (37, 38)
- CO2 exposures may cause fatigue. CO2 levels in grow rooms are typically below OSHA thresholds. (37)
- Forty-six percent of workers surveyed in Colorado reported having had little or no worker safety training since starting work. (39)
- Legalization invites new innovations and technologies into the field, with hazards constantly evolving, ozone generators and UV sanitizers have proven particularly harmful for human health if exposed. (38)

### **Questions and Answers**

Trecia.Ehrlich@lcb.wa.gov

Thank you!

- 1. Pechey, R., Burge, P., Mentzakis, E., Suhrcke, M., Marteau, T. 2014. Public acceptability of population-lalcohol consumption: A discrete choice experiment. Social Science & Medicine. Volume 113, pp 104-10.
- 2. Buykx, P., Gilligan, C., Ward, B., Kippen, R., Chapman, K., 2015. Public support for alcohol policies associated with the second cancer risk. *International Journal of Drug Policy*, Volume 26, Issue 4, pp. 371-379.
- 3. Krauss, M. J., Sowles, S. J., Sehi, A., Spitznagel, E. L., Berg, C. J., Bierut, L. J., & CavazosRehg, P. A. (2017). Convenient advecting exposure among current marijuana users in the U.S. Drug and Alcohol Dependence, 174, 192-200. http://doi.org/10.1016/j.drugalcdep.2017.01.017
- 4. Bierut, T., Krauss, M., Sowles, S., & Cavazos-Rehg, P. (2017). Exploring marijuana advertising on Weedmaps, a popular online directory. Prevention Science, 18(2), 183192. <u>http://doi.org/10.1007/s11121-016-0702-z</u>
- 5. Cavazos-Rehg, P. A., Krauss, M. J., Sowles, S. J., Murphy, G. M., & Bierut, L. J. (2017). Exposure to and content of marijuana product reviews. Prevention Science. http://dx.doi.org/10.1007/s11121-017-0818-9
- 6. Krauss, M. J., Sowles, S. J., Mylvaganam, S., Zewdie, K., Bierut, L. J., & Cavazos-Rehg, P. A. (2015). Displays of dabbing marijuana extracts on YouTube. Drug and Alcohol Dependence, 155, 45-51. http://dx.doi.org/10.1016/j.drugalcdep.2015.08.020
- 7. Cavazos-Rehg, P., Krauss, M., Grucza, R., & Bierut, L. (2014). Characterizing the followers and tweets of a marijuana focused Twitter handle. Journal of Medical Internet Research, 16(6), e157. http://dx.doi.org/10.2196/jmir.3247
- 8. Cavazos-Rehg, P. A., Sowles, S. J., Krauss, M. J., Agbonavbare, V., Grucza, R., & Bierut, L. (2016). A content analysis of tweets about high-potency marijuana. Drug and Alcohol Dependence, 166, 100-108. http://dx.doi.org/10.1016/j.drugalcdep.2016.06/034
- 9. T Freeman and A Winstock (2015) Examining the profile of high-potency cannabis and its association with severity of comabis dependence. *Psychological Medicine* 45, 3181-3189. Freeman, T., Van der Pol, P., Kuijpers, W., Wisselink, J., Das, P., Riccer, S., Lynskey, M. (2018). Changes in cannabis potency and first-time admissions to drug treatment: A 16-year study in the bellerlands. *Psychological Medicine*, 1-7. doi:10.1017/S0033291717003877
- 10. Shannon S. Rickner, Dazhe Cao, Kurt Kleinschmidt & Steven Fleming <u>A little "dab" will do ya' in: a case report of neuro-a</u> cardiotoxicity following use of cannabis concentrates <u>Clinical Toxicology</u> Vol. 55, Iss. 9, 2017

- 11. Brady, K.T., Balster, R.L., The effects of delta 9-tetrahydrocannabinol alone and in combination with on fixed-interval performance in rhesus monkeys. *Psychopharmacology* .(Berl) 1980; 72(1): 21-26.
- 12. Meier, MH. Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depender 2017. October, 179: 25-31.
- Wright, M. J., Vandewater, S. A., & Taffe, M. A. (2013). Cannabidiol attenuates deficits of visuospatial associated memory induced by Δ<sup>9</sup>tetrahydrocannabinol. *British Journal of Pharmacology*, 170(7), 1365-1373. http://doi.org/10.1111/bph.12199
- Demirakca T., Alexander Sartorius, Gabriele Ende, Nadja Meyer, Helga Welzel, Gisela Skopp, Karl Mann, Derik Hermann. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabid Drug Alcohol Depend. 2011 Apr 1; 114(2-3): 242-245. Published online 2010 Nov 2. doi: 10.1016/j.drugalcdep.2010.09.020
- 15. Wild K, Wilson H. Cannabinoid hyperemesis. BMJ Case Reports 2010;10.1136/bcr.01.2010.2605.
- 16. Richards, John R. Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department Journal of Emergency Medicine. 2017.
- 17. Habboushe, J., Rubin, A., Liu, H., Hoffman, R., The Prevalence of Cannabinoid Hyperemesis syndrome Among Regular Marijuana Smokers in an Urban Public Hospital. *Basic Clinical Pharmacology & Toxicology*. 2018. Jan 12.
- 18. Kral, A., et al. Is cannabis use associated with less opioid use among people who inject durgs? *Drug and Alcohol Dependence*. 2015. 153: 236-241.
- 19. Douglass, B., et al., Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complimentary, and Tapering Uses. *The Journal of Alternative and Complimentary Medicine*. 2017. 00:00; 1-8.
- 20. Corsi, K., et al. Effects of cannabis use on opioid injection frequency. *Drug and Alcohol Dependence*. 2015. 156: 49.
- 21. Smith, K.Z, et al. The impact of cannabis use on opioid dependence treatment: A systematic review. Drug and Alcohol Dependence. 2015. 146; 101-102

- 22. Feingold, D., Goor-Aryeh, I., Bril, S., Delayahu, Y., Lev-Ran, S.; Problematic Use of Prescription Opioids and Medicinal Cannabis Among Provide and Control Pain, *Pain Medicine*, Volume 18, Issue 2, 1 February 2017, Pages 294-306,
- 23. Borodovsky, J., Lee, D., Crosier, B., Gabrielli, J., Sargent, J., Budney, A.; U.S. cannabis legalization and use of vaping and edible product and use of va
- 24. Popova, L., et al.; Perceived harms and benefits of tobacco, marijuana, and electronic vaporizers among young adults in Colorado: and research. *Addiction*. 2017. Volume 112 pp 1821-1829.
- 25. Henry, K., Augustyn, M.; Intergenerational Continuity in Cannabis Use: The Role of Parent's Early Onset and Lifetime Disorder on Child's Early Adolescent Health. 2017. 60(1): 87-92.
- 26. Kostby, DB., Farmer, RF., Seeley, JR., Duncan, SC>, Lewinsohn, PM.; Parental transmission of risk for cannabis use disorders to offspring. Addict on 2015, (10(7):110) 1117.
- 27. Camchong, J., Lim, K., Kumra, S.; Adverse Effects of Cannabis on Adolescent Brain Development: A Longitudinal Study. Cerebral Cortex. 2017; 27. 2019
- 28. Zer-Aviv, M., Tomer, Segev, Amir, Akrav, Irit; Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behavioural Pharmacology. 2016. Volume 27(7): 561-569.
- 29. LiHL, LinH. An archaeological and historical account of cannabis in China. *Econ Bot*. 1974;28:437-447
- 30. Russo, E., Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacoogy. 2011. 1/63(7); 12/44-1364
- 31. Wade, DT. Et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized-placebo controlled study on 160 patients. Mult Scler. 2004 Aug: 10(4) 434-441.
- 32. Ziemianski D, Capler R, Tekanoff R, Lacasse A, Luconi F, Ware MA. Cannabis in medicine: a national educational needs assessment among Canadian physicians. *BMC Med Educ.* 2015;15(1):52.
- 33. Raber, J., Vandrey, R., Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. JAMA. 2015; 313 (24) 2491-2493.
- 34. Jikomes, N. Analysis of I-502 Dataset reveals Systematic Differences Between Washington State Labs. Presentation: Thursday, February 8<sup>th</sup>, 2018.
- 35. Allison, D., Heshka, S., Sepulveda, D; et al. Counting Calories-Caveat Emptor. JAMA. 1993; 270(12): 1454-1456.
- 36. Devinsky, O., Patel, AD. Et Al., Randomized, dose-ranging safety trial of cannabidiol in Dravet Syndrome. *Neurology*, 2018. 90(14) 1204-1211.
- 37. Contreras, et al., Guide to Worker Safety and Health in the Marijuana Industry. Colorado Department of Public Health & Environment. January 2017.
- 38. Ehrlich, Patricia. Identifying Health and Safety Needs in Cannabis Grow Operations. *University of Washington*. June, 2017.
- 39. Walters, et al., An overview of health and safety in the Colorado cannabis industry. *American Journal of Industrial Medicine*. March 14, 2018.